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Abstract
Background: Recent fate-mapping studies establish that microglia, the resident mononuclear phagocytes of the
CNS, are distinct in origin from the bone marrow-derived myeloid lineage. Interferon regulatory factor 8 (IRF8, also
known as interferon consensus sequence binding protein) plays essential roles in development and function of the
bone marrow-derived myeloid lineage. However, little is known about its roles in microglia.
Methods: The CNS tissues of IRF8-deficient mice were immunohistochemically analyzed. Pure microglia isolated
from wild-type and IRF8-deficient mice were studied in vitro by proliferation, immunocytochemical and
phagocytosis assays. Microglial response in vivo was compared between wild-type and IRF8-deficient mice in the
cuprizon-induced demyelination model.
Results: Our analysis of IRF8-deficient mice revealed that, in contrast to compromised development of
IRF8-deficient bone marrow myeloid lineage cells, development and colonization of microglia are not obviously
affected by loss of IRF8. However, IRF8-deficient microglia demonstrate several defective phenotypes. In vivo,
IRF8-deficient microglia have fewer elaborated processes with reduced expression of IBA1/AIF1 compared with
wild-type microglia, suggesting a defective phenotype. IRF8-deficient microglia are significantly less proliferative in
mixed glial cultures than wild-type microglia. Unlike IRF8-deficient bone marrow myeloid progenitors, exogenous
macrophage colony stimulating factor (colony stimulating factor 1) (M-CSF (CSF1)) restores their proliferation in
mixed glial cultures. In addition, IRF8-deficient microglia exhibit an exaggerated growth response to exogenous
granulocyte-macrophage colony stimulating factor (colony stimulating factor 2) (GM-CSF (CSF2)) in the presence of
other glial cells. IRF8-deficient microglia also demonstrate altered cytokine expressions in response to
interferon-gamma and lipopolysaccharide in vitro. Moreover, the maximum phagocytic capacity of IRF8-deficient
microglia is reduced, although their engulfment of zymosan particles is not overtly impaired. Defective scavenging
activity of IRF8-deficient microglia was further confirmed in vivo in the cuprizone-induced demyelination model in
mice.
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Conclusions: This study is the first to demonstrate the essential contribution of IRF8-mediated transcription to a
broad range of microglial phenotype. Microglia are distinct from the bone marrow myeloid lineage with respect to
their dependence on IRF8-mediated transcription.
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Introduction
Microglia, the resident mononuclear phagocyte (MP) sys-
tem of the CNS, play principal roles in the innate immune
response to tissue damage and invasion of foreign organ-
isms, and also in initiation and modulation of the adaptive
immune response [1-3]. Although microglia share many
common features of MPs with bone marrow (BM)-derived
monocyte lineage cells and tissue macrophages of mono-
cyte origin, recent studies have demonstrated that the
contribution of BM-derived myeloid cells to microglial
homeostasis in the steady state is a far less frequent
event than was previously believed [4,5]. Only under some
abnormal conditions such as tissue alteration following ir-
radiation to the CNS, do a subset of circulating monocytes
(Ly-6C/Gr-1hi CCR2+) become engrafted as BM-derived
microglia (BMDM) through the CNS vasculature [5].
Moreover, in vivo fate mapping studies have established
that microglia are an ontogenically distinct population in
the MP system. Microglial precursors arise from primitive
extra-embryonic hematopoiesis in the yolk sac prior to
the onset of blood circulation. These primitive MPs mi-
grate into the CNS through blood vessels independently
of the second wave of hematopoiesis within the embryo
proper, which leads to the adult (definitive) hematopoiesis
in the BM [6]. Once having colonized the CNS, embryonic
microglia are highly proliferative and strongly dependent
on colony stimulating factor 1 receptor (CSF1R)-mediated
signaling for development during embryogenesis. In mice
lacking CSF1R, the number of microglia is greatly reduced
[6,7], whereas circulating monocytes are present, indica-
ting that, in contrast to microglia, the BM-derived mono-
cytes are less dependent on CSF1R-mediated signaling for
their development [6]. These accumulating pieces of evi-
dence further support the notion that microglia are main-
tained by self-renewal as a distinct MP population without
continuous replenishment by systemic BM-derived pre-
cursors or myeloid cells, although it remains to be clarified
to what extent microglia share common molecular me-
chanisms with BM-derived MPs in their development,
maintenance, and functioning.
The molecular basis of myeloid development in the BM
hematopoiesis has been intensively studied. Among the
molecules known to be involved in myeloid development
to date, interferon regulatory factor-8 (IRF8, also known as
interferon consensus sequence binding protein (ICSBP)), a
member of the interferon regulatory factor family, acts as
an essential transcription factor for differentiation and mat-
uration of BM-derived MPs in the myeloid lineage as well
as for B cell development from hematopoietic stem cells [8-
10]. IRF8 limits the size of the bipotential granulocyte-
macrophage progenitor pool, and directs these progenitor
cells to differentiate into the monocyte lineage by stimulat-
ing expression of genes critical for MP differentiation and
by repressing a series of genes required for granulocytic dif-
ferentiation [11]. IRF8-deficient BM-derived MPs are not
generated efficiently in IRF8-deficient mice, and are also de-
fective in production of cytokines and reactive oxygen spe-
cies [12-14]. IRF8 is constitutively expressed in microglia as
well [15]. Since microglia arise from mesodermal myeloid
progenitors in the primitive hematopoiesis, which is distinct
from the development of BM-derived MPs, it is essential to
determine how IRF8 regulates development of microglia to
understand the molecular basis of distinct development of
microglia and BM-derived MPs. Moreover, given the es-
sential roles for IRF8 in the functional phenotypes of BM-
derived MPs, constitutive expression of IRF8 could also be
critical for microglial functions. Indeed, a recent study has
demonstrated an essential role for IRF8 in activation of
microglia in the spinal cord following peripheral nerve in-
jury [16].
In this study, we performed a comprehensive study of
the microglia of constitutional IRF8-null mice, and fur-
ther demonstrate essential roles for IRF8 in physiological
phenotype and function of microglia.
Materials and methods
Animals
The mouse strain with targeted null mutation in the Irf8
gene in this study was reported previously [17]. The
strain was backcrossed onto the C57BL/6J strain for
more than 5 generations. Animals were housed in stand-
ard laboratory cages with unrestricted access to food
and water, and maintained under 12 h light/dark cycles.
All procedures using the animals were approved by
the Institutional Animal Care and Use Committee of
the University of California, Davis.
Reagents and chemicals
All reagents and culture media used in this study were
purchased from SIGMA (St. Louis, MO, USA) and
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Invitrogen (Carlsbad, CA, USA), respectively, except for
the following products. Mouse anti-β-actin antibody was
from Cell Signaling Technology (Danvers, MA, USA).
Rabbit anti-IBA1/AIF1 antibody was from Wako Chemi-
cals USA (Richmond, VA, USA). Rabbit anti-IRF8 anti-
body was reported previously [18].
Cell culture
Mixed glial culture
Whole brains from 0 to 2-day-old mice were dissected
and diced into 2-mm cubes. After cleaning off meninges,
and vessels including choroidal plexus, the brain chunks
were digested by 20 units/ml papain in Earle’s buffered
salt solution supplemented with 1 mM L-cystaine, 0.5
mM EDTA, 0.36% (w/v) D-glucose, and 250 units/ml
DNase at 33°C for 90 min. Papain was inactivated by 1.5
mg/ml ovomucoid in PBS containing 1.5 mg/ml bovine
serum albumin (BSA) and 250 units/ml DNase. The sof-
tened chunks were gently triturated by passing through
a 1-ml serological pipette several times. The resulting
suspension was left for 1 minute to allow undissociated
tissues to settle down on the bottom, and then the su-
pernatant containing dissociated cells was collected to
another tube. After repeating this trituration step three
times, the obtained cell suspension was spun at 220 × g
for 15 minutes. Cells were resuspended in the MG
medium; 5% (v/v) heat-inactivated fetal bovine serum, 1×
N2 NeuroPlex supplement (Gemini Bio-Products, West
Sacramento, CA), 100 units/ml penicillin, and 100 μg/ml
streptomycin in high glucose Dulbecco’s modified Eagle’s
medium (DMEM), and plated on a poly-D-lysine-coated
T75 tissue culture flask. In some experiments, 20 ng/ml of
either macrophage colony stimulating factor (M-CSF) or
granulocyte-macrophage colony stimulating factor (GM-
CSF) was added to the culture medium at 5 days in vitro,
by which time most cultures had reached confluency.
Cultures were fed with fresh medium every other day.
Magnetic cell sorting (MACS) to isolate CD11b+ mouse
microglia
Mixed glial cells in a T75 flask were maintained in the
presence of 20 ng/ml M-CSF from day 5 to day 9
in vitro. Then cells were washed with 5 ml Ca++- and
Mg++-free Hanks’ balanced salt solution (HBSS-) and
then 1 ml trypsin-EDTA (0.05% (v/v) and 0.53 mM, res-
pectively, in HBSS-) was added. After a 3 minute-
trypsinization at 37°C, 0.5 ml of trypsin inhibitor-BSA-
DNase (0.25 mg/ml, 1.44 mg/ml and 60 units/ml, re-
spectively, in DMEM.) was added, and detached cells
were collected into a 50-ml tube containing 3.5 ml MG
medium in addition to the medium saved from the cul-
tures and from the HBSS- that had been used for wash.
Cells were collected by centrifugation at 520 × g for 5
minutes, resuspended into a mixture of 40 μl CD11b
microbeads (catalog number: 130-093-634, Miltenyi
Biotech, Auburn, CA, USA) and 160 μl ice-cold MACS
buffer (0.5% BSA, 2 mM EDTA in PBS, pH 7.2), and
incubated at 4°C for 15 minutes. After a wash with 20
ml ice-cold MACS buffer, cells were resuspended into
500 μl ice-cold MACS buffer, and then applied to a
MACS separation column LS (Miltenyi Biotech) in a
magnetic field. The column was washed with 3 ml ice-
cold MACS buffer three times and removed from the
magnetic field. Magnetic labeled cells were eluted with 5
ml MACS buffer. After centrifugation at 520 × g for 5
minutes, cells were plated on to poly-D-lysine-coated
culture ware at 1.25 × 103 cells/cm2 in MG medium.
Immunocytochemistry
Purified microglia were incubated with rat anti-CD11b
antibody (1:50; AdB Serotec, Raleigh, NC, USA) for 30
minutes. After washing with PBS three times, cells were
incubated with Alexa Fluor™ 488-conjugated goat anti-
rat IgG for 30 minutes. Cells were fixed with 4% parafor-
maldehyde at room temperature for 15 minutes, and
then permeabilized with ice-cold 100% methanol for 20
minutes. Nuclei were counterstained with 4,6-diamidio-
2-phenylindole (0.5 μg/ml, DAPI).
Immunoblots
Protein lysates were prepared in the lysis buffer as
described previously [19]. Twenty μg of protein from
each sample were size-fractioned by SDS-polyacrylamide
gel electrophoresis, transferred onto a nitrocellulose
membrane (Schleicher & Schnell, Keene, NH, USA) and
probed with primary antibodies for IRF8 (1:5000) and
AIF1/IBA1 (1:5000) for 1 h. Full range recombinant Rain-
bow Molecular Weight Markers (Amersham Biosciences,
Piscataway, NJ, USA) were used as a reference for mo-
lecular sizes. Immunoreactive signals were detected by
enhanced chemiluminescence according to the manufac-
ture’s protocol (Amersham Biosciences). Equal protein
loading was confirmed by subsequent probing with the
mouse monoclonal antibody against β-actin (1:1000) in
each experiment.
Table 1 List of the fluorochrome-labeled monoclonal
antibodies used for flow cytometry
Antigen Fluorochrome Clone Isotype Company
CD11b FITC, PE M1/70 Rat IgG2b, κ BD Biosciences
CD45 eFluor450 30-F11 Rat IgG2b, κ eBioscience
F4/80 PE BM8 Rat IgG2a, κ eBioscience
CD11c APC HL3 Ar Ham IgG1, λ2 BD Biosciences
Ly6-G FITC 1A8 Rat IgG2a, κ BD Biosciences
BD Biosciences (San Jose, CA, USA); eBioscience (San Diego, CA, USA).
Horiuchi et al. Journal of Neuroinflammation 2012, 9:227 Page 3 of 14
http://www.jneuroinflammation.com/content/9/1/227
Flow cytometry
Mixed glial cells were collected by trypsinization and
stained with anti-CD45 and anti-CD11b antibodies to-
gether with anti-F4/80, anti-CD11c, or anti-Ly-6G
antibody for 30 minutes at room temperature. Each anti-
body was diluted at 1:100 in PBS containing 1% (w/v) BSA
and Fc-blocker (1:40; BD Bioscience). Samples were
acquired by Cyan-ADP flow cytometry (DakoCytomation,
Carpinteria, CA, USA) and analyzed with Summit soft-
ware (DakoCytomation). Antibodies used for flow cytome-
try are listed in Table 1.
EdU (5-ethynyl-2′-deoxyuridine)-incorporation assay
Mixed glial cultures were incubated with 10 μM EdU for
6 h. Then, trypsinized cells were collected and stained
with FITC-conjugated rat anti-CD11b antibody (1:100;
BD Bioscience) in PBS containing 1% (w/v) BSA and Fc-
blocker (1:40) for 30 minutes at room temperature. After
washing with PBS containing 1% (w/v) BSA three times,
cells were fixed with 4% (w/v) paraformaldehyde and
permeabilized with saponin-based permeabilizing buffer.
EdU was detected using a pacific blue-conjugated azide
(Invitrogen) according to the manufacturer’s instruction.
Samples were acquired by Cyan-ADP flow cytometry,
and the number of EdU-positive cells in either CD11b-
positive or negative cell population was separately coun-
ted by gating with Summit software.
For purified microglial cultures, EdU (10 μM as a final
concentration) was added to pure microglia plated on
poly-D-lysine-coated 12 mm-diameter round cover slips at
5×104 cells/cover slip at 18 h after addition of MG alone,
or MG medium supplemented with 20 ng/ml M-CSF or
GM-CSF. After incubation for 6 h, cells were fixed and
EdU incorporated into the nucleus was detected with
azide conjugated with Alexa Fluor™ 594 according to the
manufacturer’s instruction (Click-iT™ EdU cell prolifera-
tion assay, Invitrogen). All nuclei were counted with the
aid of DAPI.
Phagocytosis assay by flow cytometry
Microglia plated on a 24-well plate were incubated with
Alexa Fluor™ 488-conjugated zymosan A particles (Invi-
trogen) at 2×106 particles/ml in the MG medium. After
wash with 0.5 ml HBSS- twice, cells were detached by
trypsinization and collected into a 15-ml tube. After cen-
trifugation at 520 × g for 5 minutes, cells were resus-
pended into 0.5 ml 0.1% (w/v) BSA in PBS, and then
analyzed by CyAn-ADP flow cytometer. Mean fluorescent
intensity (MFI) was calculated with Summit software.
Real-time PCR
Real-time PCR (qPCR) analyses were performed by
MX3005P (Stratagene, La Jolla, CA, USA) using Taq-
Man™ Assay-on-Demand™ assay kits (assay nos.:
Mm01250092_g1, Mm01270606_m1, Mm00479862_g1,
Mm00439546_s1 and Mm00434174_m1 for detection
of IRF8, PU.1/SFPI1, AIF1/IBA1, IFNB1, and IL12B
cDNA, respectively). For standardization, β-actin cDNA
levels were also quantified with the kit (Mm00607939_s1),
and the absolute cDNA amounts were expressed as ratios
to β-actin cDNA. We analyzed each gene using total RNA
samples from at least triplicated independent experiments.
Immunohistochemistry
Mice were perfusion-fixed with 4% (w/v) paraformalde-
hyde in PBS, and tissues were processed as reported pre-
viously [20]. Tissue sections (6 μm-thick) were prepared
by a cryostat (CM1950, Leica Microsystems, Watzlar,
Germany); rinsed in PBS; incubated for 30 minutes at
room temperature in a blocking solution containing
0.4% (w/w) Triton X-100, 10% (v/v) donkey serum, 15
mM HEPES, 0.02% (w/v) sodium azide in 1x minimum
essential medium; and incubated with primary anti-
bodies in the blocking solution overnight at 4°C. The
following primary antibodies were used: rat monoclonal
anti-CD11b (M1/70.15.11.5, 1:50; Developmental Studies
Hybridoma Bank, Iowa City, IA, USA), rabbit polyclonal
anti-PU.1/SFPI1 (#2266, 1:100; Cell Signaling, Danvers,
MA), rabbit polyclonal anti-IBA1/AIF1 (No. 019-19741,
1:1000; Wako Chemicals USA, Richmond, VA, USA), rat
monoclonal anti-F4/80 antigen (BM8, 1:100; eBioscience,
San Diego, CA, USA) and rabbit polyclonal anti-CD68
(No. 250594, 1:200; AB Biotec, San Diego, CA, USA).
Then, the sections were washed with PBS, incubated for 1
h in appropriate rhodamine, or Dylight 488-conjugated
secondary antibodies (1:500, Jackson Immunoresearch,
West Grove, PA, USA) at room temperature, and moun-
ted with ProLong Gold antifade reagent containing DAPI
(Invitrogen).
Cuprizone-induced demyelination in mice
Demyelination was induced by feeding wild-type (Irf8+/+)
and IRF8-deficient (Irf8-/-) male mice at 8 to 10 weeks of
age a diet of pellet feed (Harlan Laboratories, Madison,
MI, USA) containing 0.25% (w/w) cuprizone (Sigma) up
to 6 weeks. Animals were sacrificed at the indicated time
points for histological analyses.
Myelin staining and Oil Red O staining
After fixation with paraformaldehyde as described above,
brains were embedded in paraffin. Five μm-thick coronal
brain sections between bregma -1.2mm and -2.2mm were
stained with Luxol fast blue (LFB) (Sigma) for myelin to-
gether with periodic acid Schiff (PAS) for microglia and
demyelinated axons. For Oil Red O staining, mice were
perfusion fixed by 10% formalin. Brains were removed and
postfixed, and then 6 μm-thick cryosections were pre-
pared. NovaUltra™ Oil Red O Stain Kit (IHCWORLD,
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Woodstock, MD, USA) was used to stain undigested mye-
lin lipids according to the manufacture’s instruction.
Statistical analysis
Unless otherwise noted, data are presented as mean ±
SD, and statistical significance was determined by two-
tail ANOVA followed by Student-Newman-Keuls post
hoc test. Results were considered significant when
P < 0.05.
Results
IRF8-deficient microglia populated the CNS normally, but
demonstrated less complex morphology with less IBA1
expression than wild-type microglia
Our immunohistochemical analysis of microglia in the
CNS tissues of wild-type (Irf8+/+) and IRF8-deficient
(Irf8-/-) adult mice first revealed that most Irf8-/- micro-
glia could not be identified as cells positive for AIF1/
IBA1, a common marker protein for microglia. In contrast
to AIF1/IBA1, Irf8-/- microglia expressed other microglial
markers such as CD11b, CD68 and F4/80 at levels com-
parable with those of Irf8+/+ microglia. Among these
markers, we found that double immunolabeling for mem-
brane CD11b and nuclear PU.1/SFPI1 (SPI1 in humans), a
transcription factor exclusively expressed in hematopoietic
lineage cells, is the most reliable method to identify micro-
glia in both Irf8+/+ and Irf8-/- CNS tissues particularly for
quantitative analysis (Figure 1A). In the corpus callosum
and the dorsal column of the spinal cord, nearly 100% of
CD11b-positive microglia were positive for nuclear PU.1/
SFPI1. Quantitative analysis of microglia in the dorsal co-
lumn of the spinal cord using these microglial markers
revealed that the proportion of microglia to total cells was
not different between Irf8-/- and Irf8+/+ mice (Figure 1B).
These results indicate that, in contrast to compromised
development of the BM myeloid lineage in Irf8-/- mice, de-
velopment and colonization of microglia are not obviously
affected by loss of IRF8.
In addition to the reduced expression of AIF1/IBA1 in
Irf8-/- microglia, we also found a clear difference in their
morphology in vivo. Generally, Irf8+/+ microglia in the
normal CNS tissues extend elaborate and highly-branched
processes which sometimes reach a distance of more than
50 μm from the cell soma and cover a broad area. As a
good example, transverse sections of the Irf8+/+ dorsal co-
lumn contain numerous CD11b-positive processes, some
of which were from the microglia outside of the sections.
In contrast, CD11b-positive Irf8-/- microglial processes in
the dorsal column were apparently sparser than those in
the Irf8+/+ counterpart (Figure 1C, Figure 2). This dif-
ference was statistically significant when total CD11b-
positive areas in the whole cross-sectional area of the dor-
sal column were compared quantitatively between Irf8+/+
and Irf8-/- mice. We observed a similar difference in other
CNS regions such as the corpus callosum (Figure 2). Con-
focal z-stack images demonstrated that the processes of
Irf8-/- microglia were generally thick and less extended
compared with those of Irf8+/+ microglia (Figure 1C),
suggesting that, since the density of microglia was similar
between Irf8+/+ and Irf8-/- mice, Irf8-/- microglia were
Figure 1 IRF8-deficient microglia colonized the CNS normally,
but could not be identified by AIF1/IBA1 immunoreactivity. The
spinal cords obtained from adult Irf8+/+ and Irf8-/- mice were
immunolabeled for various microglial markers (A), and positive cells
in the dorsal column at the Th1 spinal level were quantified (B).
Microglia were reliably identified as CD11b and PU.1 double positive
cells in both Irf8+/+ and Irf8-/- CNS tissues (pink arrows in far left
panels in A). Note that few Irf8-/- microglia demonstrated detectable
immunoreactivity for AIF1/IBA1. Scale bar: 100 μm. **P< 0.01. (C) 20
μm-thick z-stack confocal images of the microglia immunolabeled
for CD11b (green) and PU.1 (red) in the dorsal columns at the Th1
spinal level. CD11b-positive microglial processes were much sparser
in the dorsal column of Irf8-/- mice than those in Irf8+/+ mice, and
processes of Irf8-/- microglia were thicker and less elaborated than
those of Irf8+/+ microglia. PU.1-positive microglial nuclei are
indicated by arrows, demonstrating that similar numbers of
microglia are distributed in the Irf8+/+ and Irf8-/- spinal cords in
contrast to the different density of the microglial processes. Scale
bar: 100 μm.
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defective in forming normal extended processes with
complex arborization.
IRF8-deficient microglia did not proliferate well in mixed
glial cultures, but demonstrated a hyperproliferative
response to GM-CSF
We next studied Irf8-/- microglia in vitro. We initially tried
to isolate Irf8-/- microglia by the standard ‘shaking-off ’
method from the mixed glial cultures [21]. Compared with
Irf8+/+ microglia, however, we found that Irf8-/- microglia
did not proliferate well in the mixed glial cultures, resul-
ting in a much lower yield of pure Irf8-/- microglia than
that of Irf8+/+ microglia. Reduced proliferation rates of
Irf8-/- microglia in the mixed glial cultures were confirmed
by EdU incorporation assay (Figure 3J), suggesting that
Irf8-/- microglia did not respond normally to undeter-
mined mitotic signal(s) present in the mixed glial cultures.
Since Irf8-/- BM myeloid progenitors are known to ex-
hibit altered growth response to GM-CSF, G-CSF (granulo-
cyte colony stimulating factor), and M-CSF, the cytokines
involved in proliferation and differentiation of the myeloid
lineage [22], we added M-CSF and GM-CSF to the Irf8+/+
and Irf8-/- mixed glial cultures to examine the growth re-
sponse of CD11b-positive microglia. Unlike Irf8-/- BM mye-
loid progenitors, addition of M-CSF significantly enhanced
proliferation of Irf8-/- microglia in mixed glial cultures. Im-
portantly, the rates of EdU incorporation were nearly
equivalent between Irf8+/+ and Irf8-/- microglia in the pres-
ence of M-CSF. In contrast, Irf8-/- microglia in mixed glial
cultures exhibited a hyperproliferative response to
GM-CSF compared with Irf8+/+ microglia (Figure 3J).
The lineage progression of Irf8-/- BM myeloid progenitors
Figure 2 Irf8-/- CNS tissues contain significantly less microglial
processes than Irf8+/+ tissues. (A) Dorsal columns at the Th1 spinal
level were immunolabeled for CD11b and PU.1, and inverted
confocal fluorescence images of 12 μm-thick transverse sections are
shown in monochrome. Only cross-sectional areas of the dorsal
columns are shown. The location of each microglial nucleus positive
for PU.1 is indicated by a circle to demonstrate similar distributions
of microglia between the Irf8+/+ and Irf8-/- dorsal columns, which
contrasts to lower densities of CD11b-positive microglial processes
in Irf8-/- mice than in Irf8+/+ mice. (B) Similar difference was
observed in the coronal sections of the corpus callosum. (C) The
percentages of CD11b-positive areas in the whole cross-sectional
area of the dorsal column were measured and compared
quantitatively between Irf8-/- (closed bar) and Irf8+/+ mice (open bar).
Three 3-month-old animals were used in each genotype. **P< 0.01.
Scale bar: 100 μm.
Figure 3 IRF8-deficient microglia in the mixed glial cultures
exhibited a hyperproliferative phenotype in response to M-CSF
and GM-CSF. A-I, Phase contrast images of mixed glial cultures
from Irf8+/+ (A-C), Irf8+/- (D-F), and Irf8-/- (G-I) brain tissues. Cells were
transferred to medium alone (control), medium supplemented with
M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) at 5 days in vitro, and then
maintained in the same medium for another 4 days. Most microglia
were seen as phase-bright round cells on the sheet of flat glial cells.
Scale Bar: 50 μm. (J-K) Percentages of EdU-positive cells in total
CD11b+ (J) or CD11b- (K) cells in the mixed glial cultures of the
respective genotypes. Cells treated medium alone (cont), or medium
supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) for 4
days were exposed to EdU at 6 hours prior to fixation, and double-
stained for CD11b and EdU. **P< 0.01 and N.S indicates no
significant difference in a comparison of the two groups indicated.
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is skewed toward cells of the granulocytic lineage even in
the presence of M-CSF [22]. Therefore, we further exam-
ined alteration in the myeloid phenotype of Irf8-/- micro-
glia in response to either M-CSF or GM-CSF. Our results
confirmed that M-CSF did not induce CD11c and Ly-6G,
the dendritic cell (DC) and granulocyte markers, respect-
ively, in both Irf8+/+ and Irf8-/- microglia. On the other
hand, GM-CSF reduced expression of F4/80 and increased
CD11c-positive population in Irf8-/- microglia (Figure 4).
Based on these results, we isolated microglia from both
Irf8+/+ and Irf8-/- mixed glial cultures pretreated with M-
CSF (20 ng/ml) for further in vitro analyses. To ensure the
purity and maximum yield of microglia, the cells that were
surface positive for CD11b were sorted out using MACS
anti-CD11b microbeads. In the Irf8+/+ and Irf8-/- micro-
glial cultures which we obtained by this method,
CD11b-positive cells were 96.2± 3.0% and 90.6 ± 2.3% of
total cells, respectively, at 24 h after isolation. These
Irf8+/+ and Irf8-/- microglia were difficult to distinguish by
morphology in vitro under a phase contrast microscope
(Figure 5A-D). As reported by Campbell’s group [15], con-
stitutive expression of IRF8 mRNA and protein in the iso-
lated microglia in vitro was confirmed by qPCR and
immunoblotting, respectively. IRF8 mRNA levels were
comparable to those of PU.1/SFPI1 mRNA in Irf8+/+
microglia, and further upregulated by interferon-γ but not
by lipopolysaccharide (LPS). IRF8 protein levels were
regulated in accordance with mRNA levels. No immunor-
eactivity for IRF8 was detectable in the isolated Irf8-/-
microglia (Figure 5E, F). Purified Irf8-/- CD11b+ microglia
demonstrated significantly lower EdU incorporation rates
than Irf8+/+ CD11b+ microglia in control cultures and
even in the presence of exogenous M-CSF. Interestingly,
both Irf8+/+ and Irf8-/- CD11b+ microglia no longer
demonstrated proliferative responses to exogenous
GM-CSF in the absence of concomitant other glial
cells (Figure 5G).
IRF8-deficient microglia demonstrated a reduced
maximum phagocytic capacity in vitro
Like their myeloid cousins, microglia are characterized by
their motility and phagocytic activity. Motility of Irf8+/+
and Irf8-/- microglia was analyzed in vitro by the same
time-lapse video imaging as used in our previous study
[23]. In vitro motility analysis failed to reveal significant
differences between the two genotypes (data not shown).
Alexa Fluor™ 488-conjugated zymosan particles were
added to the pure microglial cultures to assess the
phagocytic activity of Irf8+/+ and Irf8-/- microglia by flow
cytometry. Soon after addition of the particles, both
Irf8+/+ and Irf8-/- microglia started taking them up ac-
tively, and there was no difference in the percentages of
the cells containing the fluorescent particles between
Irf8+/+ and Irf8-/- microglia throughout the experiment
(Figure 6C), indicating that the molecular mechanism
necessary for internalization of zymosan functioned nor-
mally in the absence of IRF8. On the other hand, we
observed that Irf8-/- microglia contained less zymosan
particles than Irf8+/+ microglia when their phagocytic
activities reached a plateau (compare Figures 6A and
6B). In support of this observation, the averaged fluores-
cence intensity was significantly reduced in Irf8-/- micro-
glia compared with Irf8+/+ microglia at 24 hr after
addition of zymosan particles (Figure 6D). As the fluores-
cence emission or the profile of the excitation/emission
spectra of the Alexa Fluor™ dye is unchanged over the pH
range 4 to 9 [24], the averaged fluorescence intensity is
quite likely to correlate with the amount of phagocytosed
zymosan, thereby confirming that the maximum phago-
cytic capacity of Irf8-/- microglia was reduced.
Figure 4 F4/80, CD11c, and Ly-6G expression in Irf8+/+ and Irf8-/- microglia in the mixed glial cultures maintained in the presence of
M-CSF or GM-CSF. Mixed glial cells were cultured in medium alone (control) or medium supplemented with M-CSF (20 ng/ml) or GM-CSF
(20 ng/ml) for 4 days, and labeled with anti-CD45 and anti-CD11b antibodies in combination with each of anti-F4/80, anti-CD11c or anti-Ly-6G
antibodies. The bivariate plots show expression of CD11b, F4/80, CD11c and Ly-6G on gated CD45-positive cells. The quadrants were set using
corresponding isotype controls.
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IRF8 was necessary to maintain the basal transcriptional
level of AIF1/IBA1 in microglia, but not for its induction
by interferon-γ
To explore the mechanisms underlying reduced IBA1/
AIF1 expression in Irf8-/- microglia in vivo, we examined
IBA1/AIF1 expression in Irf8+/+ and Irf8-/- microglia in
vitro. In agreement with our in vivo results and another
Figure 5 Purified Irf8+/+ and Irf8-/- microglia in vitro. (A-D)
Representative phase contrast (A, B) and immunocytochemical
(C, D) pictures of the microglia isolated from the Irf8+/+ (A, C) and
Irf8-/- (B, D) mixed glial cultures grown in the presence of M-CSF
(20 ng/ml) by magnetic-activated cell sorting. Purified cells were
immunolabeled for CD11b (green in C, D) at 24 h after isolation.
Nuclei were counterstained with DAPI (blue). Scale Bar: 50 μm.
(E) IRF8 and PU.1/SFPI1 mRNA levels in the purified Irf8+/+ microglia.
Purified microglia were incubated in medium alone (control) or in
the presence of IFNγ (IFNG, 100 ng/ml), lipopolysaccharide (LPS, 100
ng/ml) or both for 24 h. Reverse transcribed IRF8 and PU.1/SFPI1
cDNA levels are plotted as ratios to copy numbers of β-actin cDNA
on a logarithmic scale. (F) Immunoblots for IRF8 confirmed the
results of mRNA. (G) Purified Irf8-/- CD11b+ microglia were less
proliferative than Irf8+/+ CD11b+ microglia even in the presence of
exogenous M-CSF. Purified microglia were preincubated with
medium alone for 24 h after isolation from Irf8+/+ (open bars) and
Irf8-/- (closed bars) mixed glial cultures, and then treated with
medium alone (control), or medium supplemented with M-CSF
(20 ng/ml) or GM-CSF (20 ng/ml) for 24 h. After a 6 hour incubation
with EdU, EdU-positive and DAPI-positive nuclei were counted.
**P< 0.01 in comparison with control or between the two groups
indicated.
Figure 6 IRF8-deficient microglia demonstrated a reduced
phagocytic capacity in vitro. Microglia from Irf8+/+ (A) and Irf8-/-
(B) mice were incubated with Alexa Fluor™ 488-conjugated
zymosan particles for 24 hours. Scale bar: 50 μm. (C-D) Percentages
of Alexa Fluor™ 488-positive cells in total cells (C) and mean
fluorescent intensity (MFI) of Alexa Fluor™ 488-positive cells (D) were
measured in Irf8+/+, Irf8+/-, and Irf8-/- microglial cultures at 0, 1, 6, and
24 hour after adding the zymosan particles. The MFI of a non-
phagocytosed Alexa Fluor™ 488-conjugated zymosan particle is also
shown (Zymosan- Alexa488) in D. **P< 0.001 in comparison with the
two groups indicated.
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study [16], Irf8-/- microglia expressed far less IBA1/AIF1
protein than Irf8+/+ microglia in the control cultures
(Figure 7B). The qPCR results also demonstrated that the
basal levels of AIF1/IBA1 mRNA in Irf8-/- microglia were
approximately five-fold lower than those in Irf8+/+ micro-
glia (Figure 7A). However, both AIF1/IBA1 mRNA and
protein were upregulated by IFNγ even in the absence of
IRF8. Interestingly, this IFNγ-mediated induction of AIF1/
IBA1 was significantly inhibited by simultaneous stimula-
tion with LPS, particularly in Irf8-/- microglia (Figure 7).
Altered cytokine induction in IRF8-deficient microglia in
response to LPS and IFNγ
In BM-derived myeloid cells, IRF8 is critically involved
in transcriptional regulation of various cytokines which
are essential for initiation and modulation of the adap-
tive immune response [14,25,26]. Among those cyto-
kines, we asked whether IRF8 regulates the
transcriptional induction of Interferon-β1 (IFNB1) and
Interleukin-12b (IL12B) in response to LPS and IFNγ
in microglia in the same manner as reported in
preceding studies using BM-derived myeloid cells. As
shown in Figure 8A, quantitative and kinetic analysis of
IFNB1 mRNA revealed that IRF8 contributes to the
transcriptional regulation of IFNB1 in microglia in at
least two ways; First, IRF8 positively regulates acute
transcriptional induction of IFNB1 in response to
LPS, which is a distinctive mode of induction in mye-
loid cells [27]. In the absence of IRF8, however, this
rapid induction of IFNB1 still occurs at approxi-
mately ten-fold lower levels. Second, IRF8 represses
IFNγ-mediated induction of IFNB1. The qPCR results
of IL12B mRNA demonstrated that IRF8 acted as a
strong transcriptional enhancer in both IFNγ- and
LPS-mediated transcriptional induction of IL12B in
microglia (Figure 8B).
Figure 7 AIF1/IBA1 expression in Irf8-/- microglia was reduced
but still inducible by IFNγ. (A) Quantitative and kinetic analysis of
AIF1/IBA1 mRNA in Irf8+/+ and Irf8-/- microglia after addition of
medium alone (Control, open circle), IFNγ (IFNG, 100 ng/ml, closed
circle), lipopolysaccharide (LPS, 100 ng/ml, open square) or both
(closed square). Reverse transcribed cDNA levels at the indicated
time points were quantified by qPCR and are plotted as ratios to
copy numbers of β-actin cDNA on a logarithmic scale. Data were
from at least three independent experiments. At time 0, data from
controls are only shown. (B) Irf8-/- microglia expressed far less
AIF1/IBA1 protein than Irf8+/+ microglia. Purified microglia were
maintained in the medium containing IFNγ (IFNG, 100 ng/ml),
lipopolysaccharide (LPS, 100 ng/ml) or both for 24 h. Subsequent
immunoblots for β-actin (ACTB) are shown for equal protein
loading.
Figure 8 Kinetics of IFNB1 (A) and IL12B (B) mRNA levels in
Irf8+/+ and Irf8-/- microglia after the exposure to IFNγ and
lipopolysaccharide. Purified microglia were incubated in medium
alone (Control, closed and open circle in the left panels) or in
the presence of IFNγ (IFNG, 100 ng/ml), lipopolysaccharide
(LPS, 100 ng/ml) or both (IFNG+ LPS) for 24 h. IFNB1 and IL12B
mRNA at the indicated time points were quantified by qPCR and are
plotted as ratios to copy numbers of β-actin cDNA on a logarithmic
scale. Data were calculated from at least three independent
experiments in each genotype. At time 0, data from controls are
only shown. **P< 0.01 and *P< 0.05, in a comparison of the two
genotypes at the indicated time points.
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IRF8-deficient microglia demonstrated a delayed response
to tissue damage and a defect in clearing damaged
tissues in the cuprizone demyelination model
We finally examined whether Irf8-/- microglia are defective
in their functions in vivo. As we consider microglia as a
myeloid population distinct from BM-derived myeloid
cells, it was essential to evaluate their functions with mini-
mum contributions of BM-derived myeloid cells from the
systemic circulation. Cuprizone-induced demyelination in
mice is an established rodent model in which cuprizone in
the diet selectively kills myelinating oligodendrocytes par-
ticularly in the corpus callosum. Importantly, the blood
brain barrier remains intact during this intoxication [28],
and contributions of BM-derived MPs and T lymphocytes
from the circulation are quantitatively small [29,30]. We
first confirmed that numbers of microglia, myelinating oli-
godendrocytes, and their precursors that are recognized
by surface expression of NG2 chondroitin sulfate
proteoglycan (CSPG4) were not altered quantitatively in
the corpus callosum of Irf8-/- mice before cuprizone in-
toxication (Figure 9A). Six week-feeding with 0.25% (w/w)
cuprizone induced demyelination in the corpus callosum
in both Irf8+/+ and Irf8-/- mice, although more myelin
remained in the corpus callosum of Irf8-/- mice than in
Irf8+/+ mice. However, surviving myelinating oligodendro-
cytes labeled with CC1 monoclonal antibody were
reduced similarly in both Irf8+/+ and Irf8-/- mice during
cuprizone feeding, indicating the same cytotoxicity
of cuprizone to Irf8+/+ and Irf8-/- oligodendrocytes
(Figure 9B). Nevertheless, we found delayed accumulation
of microglia double labeled with CD11b and PU.1/SFPI1
in the demyelinated corpus callosum of Irf8-/- mice. Inter-
estingly, the activated Irf8-/- microglia had characteristic
CD11b-positive oval cell soma with a clear margin,
whereas activated Irf8+/+ microglia extended CD11b-
positive cell soma diffusely, which made it difficult to dis-
tinguish each Irf8+/+ microglia by single label staining for
CD11b (Figure 9C). More notably, oil red O staining
which visualized myelin lipids revealed accumulation of
myelin debris in Irf8-/- mice, indicating defective scaven-
ging activity of Irf8-/- microglia (Figure 9D).
Discussion
The first finding in this study is that, even in the absence
of IRF8, microglia can develop and colonize the CNS.
This contrasts clearly to inefficient development of BM-
derived MPs and accumulation of myeloid progenitor
cells in Irf8-/- mice [11], and indicates that IRF8-me-
diated transcriptional regulation is not necessary for
Figure 9 A defective phenotype of IRF8-deficient microglia
in vivo in the cuprizone-induced demyelination model. (A)
There was no quantitative difference in corpus callosal microglia,
myelinating oligodendrocytes, and NG2-positive oligodendroglial
precursor cells between Irf8+/+ and Irf8-/- mice before cuprizone
feeding. Microglia and myelinating oligodendrocytes were identified
by immunoreactivity for nuclear PU.1 and for the cytosolic CC1
epitope, respectively. (B) Cuprizone-mediated demyelination in the
medial corpus callosum in Irf8+/+ and Irf8-/- mice. Representative
LFB-PAS-stained paraffin sections of the medial corpus callosi of
Irf8+/+ and Irf8-/- mice at 4 and 6 weeks of cuprizone diet (left panel).
Scale bar: 100 μm. Reduction of myelinating oligodendrocytes in the
corpus callosum. CC1+ oligodendrocytes per unit area of 6 μm-thick
coronal sections were counted. At least three mice were used for
each data point (right graph). (C) Microglial accumulation in the
corpus callosum was delayed in Irf8-/- mice compared with Irf8+/+
mice. CD11b+ microglia with PU.1+ nuclei were quantified in 6 μm-
thick coronal sections as in B (right graph). Note that the abnormal
oval cell shape of activated Irf8-/- microglia at 6 weeks of cuprizone
feeding. Scale bar: 100 μm. (D) Oil red O plus hematoxylin staining
of the corpus callosum of Irf8+/+ and Irf8-/- mice at 0, 4 and 6 weeks
of cuprizone feeding. Lipid-rich myelin debris visualized by Oil red O
staining (red arrows) rapidly accumulated in the corpus callosum of
Irf8-/- mice, as demyelination progressed. Scale bar: 25 μm. Data are
presented as mean± standard error. *P<0.05 by Mann-Whitney U test.
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development of microglia in the primitive hematopoiesis
and for their migration into the embryonic CNS. On the
other hand, loss of PU.1/SFPI1 blocks MP development
as early as the primitive hematopoiesis in the yolk sac,
resulting in lack of tissue residential MPs including
microglia, liver Kupffer cells, and lung alveolar macro-
phages [31]. IRF8 is known to associate with PU.1/SFPI1
to activate transcription of some genes by interacting
with the composite Ets/IRF-cis elements in the promoter
region [32,33]. However, our result indicates that PU.1/
SFPI1 does not require IRF8 to exert its critical roles in
development of microglia. After migration into the CNS,
a large proportion of the adult microglial cell population
arises during the first two postnatal weeks by an intense
in situ proliferation in proportion to the growth of the
CNS tissues [34]. Based on the observations on the mu-
tant mice lacking CSF1R [7,35] or one of its ligands, M-
CSF [36,37], this perinatal expansion of the microglial
population size is largely dependent on mitotic signals
mediated by the M-CSF receptor CSF1R/CD115. We
can conclude from our in vivo and in vitro experiments
that, even in the absence of IRF8, microglia can respond
to M-CSF and proliferate.
However, colonized IRF8-deficent microglia are not
phenotypically and functionally equivalent to wild-type
microglia. An obvious difference is that the processes of
Irf8-/- microglia in the steady state are less extended into
the tissues compared to those of Irf8+/+ microglia. Re-
cent two-photon in vivo or ex vivo imaging has revealed
that, although ramified microglia in the steady state have
been referred as ‘resting’ microglia, their processes are
highly dynamic to probe changes actively in their micro-
environment [38] and to monitor neuronal synaptic ac-
tivities [39]. If microglia detect tissue damage, their
processes can quickly converge to form a barrier to con-
tain a damaged area from the surrounding healthy tissue
[40,41]. Our observation suggests that Irf8-/- microglia
may be less capable of sensing tissue damage due to
their less extended processes. IRF8-deficent microglia
will provide a unique model for further understanding of
process dynamics and sensing capability of microglia.
Reduced expression of AIF1/IBA1 is also a prominent
feature of Irf8-/- microglia [16]. As far as we could exa-
mine, however, AIF1/IBA1 is the only microglial marker
affected by loss of IRF8, indicating again that a major
part of microglial development occurs normally in the
absence of IRF8. Our analysis of AIF1/IBA1 mRNA and
protein levels demonstrated that IRF8 is required to
maintain the constitutive expression of AIF1/IBA1 in
microglia, whereas AIF1/IBA1 is still inducible in Irf8-/-
microglia by IFNγ. AIF1/IBA1, a 17-kDa protein bearing
two EF-hand Ca2+ binding motifs, is known to contrib-
ute to the plasma membrane and cytoskeleton dynamics
tightly linked to motility and phagocytosis of microglia
[42]. It is thereby reasonable to speculate that impaired
process formation in Irf8-/- microglia might be a conse-
quence of reduced AIF1/IBA1 expression. Despite the re-
port that AIF1/IBA1 is involved in the formation of
phagocytic cups in a microglial cell line [42], however, en-
gulfment of zymosan particles occurred in Irf8-/- microglia
in the same time frame as that in Irf8+/+ microglia, indi-
cating that the molecular mechanisms underlying a series
of microglial responses from chemotaxis to phagocytosis
[43] are not impaired by the reduction of AIF1/IBA1 pro-
tein. A hypothetical explanation for this discrepancy
would be that the trace amount of AIF1/IBA1 protein in
Irf8-/- microglia might be sufficient for the phagocytic
responses. Alternatively, AIF1L/IBA2, a homolog of AIF1/
IBA1, might compensate the reduced AIF1/IBA1 [44].
Basal expression of AIF1/IBA1 mRNA in Irf8-/- microglia,
though it is five-fold reduced, is likely to be attributable to
PU.1/SFPI1 that was expressed at the levels similar to
those in Irf8+/+ microglia, because PU.1/SFPI1 has been
shown to bind to the promoter region of the aif1/iba1
gene and act as a transcriptional activator [45]. Further
studies will be necessary to determine whether IRF8
enhances expression of AIF1/IBA1 directly or indirectly in
cooperation with PU.1/SFPI1 in microglia.
In contrast to normal zymosan engulfment, the maxi-
mum phagocytic capacity of Irf8-/- microglia is reduced as
determined by the amount of zymosan particles engulfed
in each microglia. After engulfment, phagosomes contai-
ning internalized materials such as bacteria and apoptotic
cell corpse undergo a maturation process along with se-
quential changes in integral membrane proteins and pro-
gressive acidification, and eventually fuse with lysosome
structures to form phagolysosomes, leading to degradation
of the contents [46,47]. IRF8-mediated transcriptional
regulation might be involved in this highly organized mat-
uration process of phagosomes, or cell structural changes
associated with the phagocytic activities. Defective scaven-
ging activity of Irf8-/- microglia was also observed in our
in vivo experiment using the cuprizone-induced demyelin-
ation model. More myelin debris rich in lipids remained
in the corpus callosum of Irf8-/- mice. However, this
in vivo result may be attributable not only to reduced
phagocytic capacity of Irf8-/- microglia, but also to de-
layed accumulation of Irf8-/- microglia in the demye-
linating lesions.
After development of the CNS, microglia continue to
cycle slowly [48], and are capable of accelerated prolifera-
tion particularly in response to tissue damages [30,49,50].
Although the molecular basis of this proliferative response
associated with microglial activation might differ de-
pending on the pathological conditions, CSF1R/CD115-
mediated signaling is principally involved in microglial
proliferation in some types of CNS lesions such as facial
motoneuron death after axotomy [51,52]. Microglia also
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proliferate in vitro in response to various cytokines includ-
ing M-CSF, GM-CSF, interleukins-3, -4, and -5 [53-57].
An interesting finding in our in vitro experiments was that
Irf8-/- microglia demonstrated significantly reduced pro-
liferation in mixed glial cultures, whereas exogenous M-
CSF restored proliferation of Irf8-/- microglia at a rate
comparable to that of Irf8+/+ microglia. Exogenous M-
CSF also enhanced proliferation of purified CD11b+
Irf8-/- microglia, but to a lesser extent compared with
purified CD11b+ Irf8+/+ microglia, suggesting that IRF8-
dependent transcription in microglia is required for their
normal proliferative response to M-CSF at a physiological
concentration. Since a previous in vitro study using M-
CSF-deficient mice indicated that M-CSF derived from
astroglia principally contributes to microglial proliferation
in mixed glial cultures [58], however, IRF8-dependent
mechanisms in astroglia might be involved in secretion
of colony stimulating factors including M-CSF from as-
troglia. In addition, the reduced proliferative response of
Irf8-/- microglia in the mixed glial cultures could at least
partly account for delayed accumulation of Irf8-/- micro-
glia in the cuprizone-induced demyelinated lesions.
GM-CSF is known to be a potent mitogen for wild-
type microglia in vitro as well [53,56,59]. In mixed glial
cultures, Irf8-/- microglia demonstrated a hyperprolifera-
tive response to GM-CSF compared with Irf8+/+ micro-
glia, which is quite likely to be identical to that observed
with Irf8-/- BM-derived myeloid progenitor cells [22].
However, our results indicated that this hyperprolifera-
tive response of Irf8-/- microglia requires the presence of
other glial cells, because exogenous GM-CSF failed to
enhance proliferation of Irf8-/- microglia after isolation
from other glial cells. A straightforward explanation for
these findings is that GM-CSF acts indirectly on mi-
croglia through GM-CSF-mediated production of other
mitogenic factor(s) from astroglia, and that IRF8 is
involved in the proliferative response of microglia to
these factors. Since some prior studies have pointed out
that, in the absence of astroglia, GM-CSF failed to in-
duce proliferation of microglia particularly from adult
animals [60,61], it is also conceivable that GM-CSF-
induced proliferation of microglia is dependent on their
maturational and activation stages. Further studies will
determine whether microglia share the same IRF8-
dependent intracellular signaling pathways leading to the
mitotic response to GM-CSF as BM-derived myeloid
progenitor cells [62,63]. GM-CSF also induces a pheno-
typic skew of microglia towards DC-like cells, but not
towards granulocytes [60]. We observed that this pheno-
typic skew was more apparent in Irf8-/- microglia than in
Irf8+/+ microglia. Given that IRF8 positively regulates de-
velopment of diverse BM-derived DC subsets in a
subset-selective manner [64], roles for IRF8 in microglial
differentiation towards a DC phenotype in the presence
of GM-CSF might be distinct from those in BM-derived
common DC progenitors.
We also confirmed that Irf8-/- microglia have the same
abnormality in the transcriptional induction of IFNB1
and IL12B as that reported in Irf8-/- BM-derived myeloid
lineage cells. Our quantitative and kinetic analysis of
IFNB1 mRNA clearly demonstrated that IRF8 positively
regulates LPS-mediated (Toll-like receptor 4-mediated)
acute induction of IFNB1 mRNA, whereas it suppresses
IFNγ-mediated delayed transcriptional induction in
microglia. Recently, Li et al. reported that, using human
monocytes, IRF8 positively regulates rapid and robust
induction of IFNβ in cooperation with IRF3 and PU.1,
and that this mode of induction is characteristic to
monocytes [27]. Our result is in good agreement with
their findings, indicating that microglia utilize the same
transcriptional machinery in the IFNB1 promoter as
BM-derived monocytes. IRF8 is also an essential trans-
cription factor for induction of IL12 p40 subunit in BM-
derived MPs [14,26]. Although our result confirmed the
same positive regulatory role for IRF8 in microglia, we
also noticed that LPS-mediated IL12B mRNA induction
still occurred in the absence of IRF8 at ten-fold lower
levels, suggesting the presence of a compensatory me-
chanism in microglia.
Our study provides further evidence for differences
between microglia and BM-derived MPs with respect to
the dependence of their development and physiological
phenotypes on IRF8-mediated transcriptional regulation.
Detailed gene expression analysis of Irf8+/+ and Irf8-/-
microglia, and Irf8+/+ and Irf8-/- BM-derived MPs will be
necessary to clarify the downstream events leading to the
difference in gene expression profiles between microglia
and BM-derived MPs [65,66].
Conclusions
In conclusion, our comprehensive analyses of IRF8-defi-
cient microglia demonstrate that IRF8 is a critical trans-
cription factor for a broad range of microglial functions,
some of which are unique in microglia. In line with our
findings, recent studies have revealed direct association of
IRF8 with human disease conditions [67,68]. This study
warrants future studies to enhance understanding of cri-
tical contributions of IRF8-mediated transcriptional regu-
lation to physiological and pathological roles of microglia.
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